Novavax Inc. (NASDAQ:NVAX) went up by 9.93% from its latest closing price compared to the recent 1-year high of $277.80. The company’s stock price has collected 17.49% of gains in the last five trading sessions. Barron’s reported on 06/08/22 that FDA Advisors Back Novavax’s Covid Shot, Clearing Way for Authorization.
Is It Worth Investing in Novavax Inc. (NASDAQ :NVAX) Right Now?
Plus, the 36-month beta value for NVAX is at 1.75. Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Novavax Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $151.86, which is $109.69 above the current price. NVAX currently public float of 75.90M and currently shorts hold a 15.94% ratio of that float. Today, the average trading volume of NVAX was 5.92M shares.
NVAX’s Market Performance
NVAX stocks went up by 17.49% for the week, with a monthly drop of -22.16% and a quarterly performance of -42.11%, while its annual performance rate touched -74.87%. The volatility ratio for the week stands at 11.83% while the volatility levels for the past 30 days are set at 12.71% for Novavax Inc. The simple moving average for the period of the last 20 days is -1.64% for NVAX stocks with a simple moving average of -62.25% for the last 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with BofA Securities repeating the rating for NVAX by listing it as a “Underperform.” The predicted price for NVAX in the upcoming period, according to BofA Securities is $35 based on the research report published on May 20th of the current year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $265, previously predicting the price at $315. The rating they have provided for NVAX stocks is “Buy” according to the report published on February 23rd, 2022.
Jefferies gave a rating of “Buy” to NVAX, setting the target price at $198 in the report published on February 22nd of the current year.
NVAX Trading at -9.95% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.63% of loss for the given period.
Volatility was left at 12.71%, however, over the last 30 days, the volatility rate increased by 11.83%, as shares sank -14.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.56% lower at present.
During the last 5 trading sessions, NVAX rose by +17.49%, which changed the moving average for the period of 200-days by -82.44% in comparison to the 20-day moving average, which settled at $45.84. In addition, Novavax Inc. saw -68.21% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NVAX starting from YOUNG JAMES F, who sale 12,500 shares at the price of $73.58 back on Mar 31. After this action, YOUNG JAMES F now owns 62,590 shares of Novavax Inc., valued at $919,765 using the latest closing price.
Herrmann John A III, the EVP, Chief Legal Officer of Novavax Inc., sale 5,000 shares at $140.91 during a trade that took place back on Jan 03, which means that Herrmann John A III is holding 3,845 shares at $704,534 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -147.13 for the present operating margin
- +98.90 for the gross margin
The net margin for Novavax Inc. stands at -152.12. Equity return is now at value -572.50, with -49.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.90.